Jing Di1, Ibrar Siddique1, Zizheng Li1, Ghattas Malki1, Simon Hornung1,2, Suman Dutta1, Ian Hurst1, Ella Ishaaya1, Austin Wang1, Sally Tu1, Ani Boghos1, Ida Ericsson1, Frank-Gerrit Klärner3, Thomas Schrader3, Gal Bitan4,5,6. 1. Department of Neurology, David Geffen School of Medicine, University of California, Gordon Neuroscience Research Building, Room 451, 635 Charles E. Young Drive South, Los Angeles, CA, 90095-7334, USA. 2. Present Address: Division of Peptide Biochemistry, Technical University of Munich, Freising, Germany. 3. Faculty of Chemistry, University of Duisburg-Essen, Essen, Germany. 4. Department of Neurology, David Geffen School of Medicine, University of California, Gordon Neuroscience Research Building, Room 451, 635 Charles E. Young Drive South, Los Angeles, CA, 90095-7334, USA. gbitan@mednet.ucla.edu. 5. Brain Research Institute, University of California, Los Angeles, CA, USA. gbitan@mednet.ucla.edu. 6. Molecular Biology Institute, University of California, Los Angeles, CA, USA. gbitan@mednet.ucla.edu.
Abstract
BACKGROUND: Molecular tweezers (MTs) are broad-spectrum inhibitors of abnormal protein aggregation. A lead MT, called CLR01, has been demonstrated to inhibit the aggregation and toxicity of multiple amyloidogenic proteins in vitro and in vivo. Previously, we evaluated the effect of CLR01 in the 3 × Tg mouse model of Alzheimer's disease, which overexpresses mutant human presenilin 1, amyloid β-protein precursor, and tau and found that subcutaneous administration of the compound for 1 month led to a robust reduction of amyloid plaques, neurofibrillary tangles, and microgliosis. CLR01 also has been demonstrated to inhibit tau aggregation in vitro and tau seeding in cell culture, yet because in Alzheimer's disease (AD) and in the 3 × Tg model, tau hyperphosphorylation and aggregation are thought to be downstream of Aβ insults, the study in this model left open the question whether CLR01 affected tau in vivo directly or indirectly. METHODS: To determine if CLR01 could ameliorate tau pathology directly in vivo, we tested the compound similarly using the P301S-tau (line PS19) mouse model. Mice were administered 0.3 or 1.0 mg/kg per day CLR01 and tested for muscle strength and behavioral deficits, including anxiety- and disinhibition-like behavior. Their brains then were analyzed by immunohistochemical and biochemical assays for pathological forms of tau, neurodegeneration, and glial pathology. RESULTS: CLR01 treatment ameliorated muscle-strength deterioration, anxiety-, and disinhibition-like behavior. Improved phenotype was associated with decreased levels of pathologic tau forms, suggesting that CLR01 exerts a direct effect on tau in vivo. Limitations of the study included a relatively short treatment period of the mice at an age in which full pathology is not yet developed. In addition, high variability in this model lowered the statistical significance of the findings of some outcome measures. CONCLUSIONS: The findings suggest that CLR01 is a particularly attractive candidate for the treatment of AD because it targets simultaneously the two major pathogenic proteins instigating and propagating the disease, amyloid β-protein (Aβ), and tau, respectively. In addition, our study suggests that CLR01 can be used for the treatment of other tauopathies in the absence of amyloid pathology.
BACKGROUND: Molecular tweezers (MTs) are broad-spectrum inhibitors of abnormal protein aggregation. A lead MT, called CLR01, has been demonstrated to inhibit the aggregation and toxicity of multiple amyloidogenic proteins in vitro and in vivo. Previously, we evaluated the effect of CLR01 in the 3 × Tg mouse model of Alzheimer's disease, which overexpresses mutant human presenilin 1, amyloid β-protein precursor, and tau and found that subcutaneous administration of the compound for 1 month led to a robust reduction of amyloid plaques, neurofibrillary tangles, and microgliosis. CLR01 also has been demonstrated to inhibit tau aggregation in vitro and tau seeding in cell culture, yet because in Alzheimer's disease (AD) and in the 3 × Tg model, tau hyperphosphorylation and aggregation are thought to be downstream of Aβ insults, the study in this model left open the question whether CLR01 affected tau in vivo directly or indirectly. METHODS: To determine if CLR01 could ameliorate tau pathology directly in vivo, we tested the compound similarly using the P301S-tau (line PS19) mouse model. Mice were administered 0.3 or 1.0 mg/kg per day CLR01 and tested for muscle strength and behavioral deficits, including anxiety- and disinhibition-like behavior. Their brains then were analyzed by immunohistochemical and biochemical assays for pathological forms of tau, neurodegeneration, and glial pathology. RESULTS: CLR01 treatment ameliorated muscle-strength deterioration, anxiety-, and disinhibition-like behavior. Improved phenotype was associated with decreased levels of pathologic tau forms, suggesting that CLR01 exerts a direct effect on tau in vivo. Limitations of the study included a relatively short treatment period of the mice at an age in which full pathology is not yet developed. In addition, high variability in this model lowered the statistical significance of the findings of some outcome measures. CONCLUSIONS: The findings suggest that CLR01 is a particularly attractive candidate for the treatment of AD because it targets simultaneously the two major pathogenic proteins instigating and propagating the disease, amyloid β-protein (Aβ), and tau, respectively. In addition, our study suggests that CLR01 can be used for the treatment of other tauopathies in the absence of amyloid pathology.
Entities:
Keywords:
Alzheimer’s disease; Immunohistochemistry; Mouse model; Seeding; Small molecule; Tauopathy
Authors: Zhuohao He; Jing L Guo; Jennifer D McBride; Sneha Narasimhan; Hyesung Kim; Lakshmi Changolkar; Bin Zhang; Ronald J Gathagan; Cuiyong Yue; Christopher Dengler; Anna Stieber; Magdalena Nitla; Douglas A Coulter; Ted Abel; Kurt R Brunden; John Q Trojanowski; Virginia M-Y Lee Journal: Nat Med Date: 2017-12-04 Impact factor: 53.440
Authors: Woo Shik Shin; Jing Di; Qin Cao; Binsen Li; Paul M Seidler; Kevin A Murray; Gal Bitan; Lin Jiang Journal: Alzheimers Res Ther Date: 2019-10-18 Impact factor: 6.982
Authors: Hedieh Shahpasand-Kroner; Jennifer Portillo; Carter Lantz; Paul M Seidler; Natalie Sarafian; Joseph A Loo; Gal Bitan Journal: Protein Sci Date: 2022-01-07 Impact factor: 6.993
Authors: Jing Di; Ibrar Siddique; Zizheng Li; Ghattas Malki; Simon Hornung; Suman Dutta; Ian Hurst; Ella Ishaaya; Austin Wang; Sally Tu; Ani Boghos; Ida Ericsson; Frank-Gerrit Klärner; Thomas Schrader; Gal Bitan Journal: Alzheimers Res Ther Date: 2021-04-22 Impact factor: 8.823